Advertisement

Psychopharmacology

, Volume 80, Issue 3, pp 236–239 | Cite as

Pharmacokinetics of chlorazepate after intravenous and intramuscular administration

  • Åke Bertler
  • Sune Lindgren
  • Jan-Olof Magnusson
  • Harry Malmgren
Original Investigations

Abstract

Dichlorazepate (DPC) was given to eight healthy volunteers aged 22–38 years (five males and three females). The dose was 20 mg (48.9 μmol) given either as an IV or an IM injection. The interval between the injections was at least 1 week. Plasma samples were analysed for desmethyldiazepam (DMD) by HPLC before and after acid hydrolysis. The kinetics after both IV and IM administration could be explained by a one or two compartment open model. By comparing values before and after hydrolysis an estimate of di- and/or monopotassiumchlorazepate (MPC) could be made. The bioavailability was almost 100% after IM administration. The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).

Key words

Benzodiazepines Dipotassium chlorazepate N-Desmethyldiazepam Pharmacokinetics after intravenous and intramuscular administration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bertler Å, Lindgren S, Malmgren H (1980) Pharmacokinetics of dipotassium clorazepate in patients after repeated 50 mg oral doses. Psychopharmacology 71:165–167Google Scholar
  2. Chun AHC, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD (1977) Effect of antacids on absorption of clorazepate. Clin Pharmacol Ther 22:329–335Google Scholar
  3. von Hattingberg HM, Brockmeier D, Kreuter G (1977) A rotating iterative procedure (RIP) for estimating hybrid constants in multicompartment analysis on desk computers. Eur J Clin Pharmacol 11:381–388Google Scholar
  4. Hillestad L, Hansen T, Melsom H, Drivenes A (1974) Diazepam metabolism in normal man. I. Serum concentration and clinical effects after intravenous, intramuscular and oral administration. Clin Pharmacol Ther 16:479–484Google Scholar
  5. Ochs HR, Greenblatt DJ, Allen MD, Harmatz JS, Shader RI, Bodem G (1978) Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clin Pharmacol Ther 26:449–456Google Scholar
  6. Rey E, d'Athis Ph, Giraux P, de Lauture D, Turquais LM, Chavinie J, Olive G (1979a) Pharmacokinetics of clorazepate in pregnant and non-pregnant women. Eur J Clin Pharmacol 15:175–180Google Scholar
  7. Rey E, Giraux P, d'Athis Ph, Turquais JM, Chavinie J, Olive G (1979b) Pharmacokinetics of the placental transfer and distribution of clorezepate and its metabolite nordiazepam in the feto-placental unit and in the neonate. Eur J Clin Pharmacol 15:181–185Google Scholar
  8. Schick AR, Dellenbach P, Müller P (1977) Etude de l'activite d'un anxiolytique administré par voie intra-veineuse au cours de l'accouchement et de ses effets sur la fréquence cardiaque foetal. Rev Fr Gynécol 72:155–160Google Scholar
  9. Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD (1978) Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminium hydroxide. Clin Pharmacol Ther 24:308–315Google Scholar
  10. Staak M, Moosmayer A, Besserer K, Speidel K, Kleinschmidt A (1982) Pharmakokinetische Untersuchungen nach oraler and parenteraler Applikation von Dikalium-Chlorazepat. Arzneim Forsch 32(1), Nr 3:272–275Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Åke Bertler
    • 1
  • Sune Lindgren
    • 1
  • Jan-Olof Magnusson
    • 1
  • Harry Malmgren
    • 1
  1. 1.Department of Clinical PharmacologyUniversity Hospital, University of Linköping and AB LeoHelsingborgSweden

Personalised recommendations